Thermo Fisher Scientific has announced that the University of Dublin has purchased the Maybridge Ro3 diversity fragment library for use in a new drug-discovery programme.
With possible applications in the fight against viral replication, bacterial infections and Alzheimer's disease, this research has the potential to provide significant therapeutic advances.
Dr Neil Ferguson's team - the UCD Biomolecular Interactions Group - combines biophysical and structural biology methodologies to unravel the molecular structures and forces that cause human diseases.
By incorporating the Maybridge Ro3 library into his existing multi-disciplinary approach, Dr Ferguson adds a new dimension to his team's research and their ability to identify potential drug compounds.
The Ro3 library will enable the team to pursue challenging targets (such as those incompatible with conventional HTS programmes), neglected diseases and, in many cases, new targets emerging from his basic research programmes.
The Maybridge Ro3 Diversity Fragment library is a resource of more than 1,500 hand-selected, compound fragments and small-molecule pharmacophores.
Selection criteria include the compliance with the 'Rule of Three' (Ro3) for lead generation and for the solubility profile of the compound.
This diverse fragment library is available as three 500-compound sets; each compound in the library is pre-solubilised as a 1ml, 10mm solution, providing 10uMol of 95-per-cent-purity material dissolved in analytical grade DMSO.
